WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in China and the United States, today announced that it updated its 2013 financial guidance. The company expects to achieve total revenues for full-year 2013 of approximately $578 million. The company expects diluted EPS for full-year 2013 to slightly exceed the top end of its previous guidance of $1.51-$1.55 (GAAP) and $1.73-$1.77 (non-GAAP). These preliminary 2013 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes. The company plans to report its fourth-quarter and full-year 2013 financial results and to provide 2014 financial guidance in March 2014.

The company also announced that it will present at the 32th annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 8:30 a.m. Pacific Standard Time. The company's slides from the conference will be available on the company's Investor Relations page at www.wuxiapptec.com.

For more information, please contact:

Ronald Aldridge (for investors)
Director, Investor Relations
Tel: +1-201-585-2048
Email: [email protected]

Aaron Shi (for the media)
Assistant Director, Corporate Communications
Tel: +86-21-5046-4362
Email: [email protected]

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking statements in this press release include statements about the anticipated results for 2013, which remain subject to the finalization of the company's year-end closing, reporting, and audit processes. Although the company believes that its predictions are reasonable, future events are inherently uncertain, and its forward-looking statements may turn out to be incorrect. The company's forward-looking statements are subject to risks relating to, among other things, its ability to cost-effectively manage its chemistry service offerings, to meet goals for the expansion of its biologics service offerings, to protect its clients' intellectual property, and to compete effectively. Additional information about these and other relevant risks can be found in the company's Annual Report on Form 20-F for the year ended December 31, 2012. The forward-looking statements in this press release speak only as of the date on which they are made, and the company assumes no obligation to update any forward-looking statements except as required by law.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are useful for understanding and assessing underlying business performance and operating trends, and the company believes that management and investors benefit from referring to these non-GAAP financial measures in assessing the company's financial performance and liquidity and when planning and forecasting future periods. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies. Because the company's financial performance is subject to finalization of its year-end closing, reporting, and audit processes, the company does not provide a specific non-GAAP to US GAAP reconciliation. A reconciliation will be provided with the company's earnings release covering its fourth-quarter and full-year 2013 results. The non-GAAP guidance presented above is consistent with the presentation of non-GAAP results as reported in the company's March 7, 2013 press release covering its fourth-quarter and full-year 2012 results.

SOURCE WuXi PharmaTech

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED